tbuckley/cabot-search huggingface dataset:
Erythema Infectiosum
Authors: William B. Wadlington
Journal: JAMA (1965)

ERYTHEMA INFECTIOSUM is an acute communicable disease characterized by the abrupt appearance of a fiery-red exanthem on the cheeks, which spreads to the rest of the body, disappears and reappears intermittently, and vanishes after a few days or weeks. It is occasionally associated with mild constitutional symptoms. This benign disease, which usually involves children from 3 to 12 years of age, is recognized infrequently unless it occurs in epidemics. It is of interest that in such comprehensive textbooks of pediatrics as Nelson (ed 7, 1959) and Holt and McIntosh (ed 13, 1962) this disease is not listed in the index. Since many physicians are unfamiliar with this disease, it is the purpose of this paper to describe the clinical picture and some of the epidemiologic aspects of erythema infectiosum. <h3>Historical Note</h3> This disease was first reported by Tschamer<sup>1</sup>in 1889, and up until 1941 there were about 50 epidemics reported,
Vertical transmission of type B hepatitis
Authors: J. W. Mosley
Journal: JAMA (1972)

Until recently it was commonly assumed that type B hepatitis must be due to a virus ecologically dependent upon practices associated with modern medicine—transfusion, vaccination, and extensive use of parenteral medications. Indeed, between 1883 and the late 1940s, the overwhelming frequency of its recognition in circumstances involving percutaneous medical procedures made this idea plausible. At present, quite apart from sharing of injection equipment among illicit drug users, it is evident that the epidemiology of this disease is multifaceted and much more complex than we thought. There is evidence for, or speculation about, very close personal contact, sexual contact, and various forms of subtle percutaneous transmission including mechanical spread by biting insects. The test for hepatitis-associated antigen (HAA), also called hepatitis B antigen, now provides a definitive means, whenever it is positive, for demonstrating infection with the type B agent, even in the absence of clinical or biochemical abnormalities. As a
CLUB DOCTORING AGAIN.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Implementing the report of the Ad Hoc Committee on Education for Family Practice
Authors: V. E. Wilson
Journal: JAMA (1969)

The Ad Hoc Committee on Education for Family Practice was appointed in September 1964, by the Council on Medical Education of the American Medical Association (AMA) with the concurrence of the AMA Board of Trustees and given the following charge: To review present AMA policy regarding the future of family and/or general practice and determine whether the goals of such policy are being achieved. To recommend the educational approach by which present goals may be achieved if they are not now being achieved. To define and recommend policies by which these goals may be achieved. <h3>History</h3><h3>Formation.—</h3> For a substantial period of years, the AMA House of Delegates had repeatedly emphasized the importance of family practice in the pursuit of optimum health care for the public, but the number and percentage of recognized family practitioners had continued to decline. The House firmly indicated its desire to reverse
Terms used to describe trials may have different meanings for patients
Journal: BMJ (1998)

Terms used to describe trials may have different meanings for patientsLittle is known about patients' perspectives of participation in randomised controlled trials.On p 1177 Featherstone and Donovan explore the understandings of randomisation among middle aged and elderly men participating in a trial of treatments for benign prostatic disease.Most men were able to recall and describe basic aspects of randomisation such as the involvement of chance, but they also developed alternative accounts to help them make sense of their experiences.The use of terms with different meanings for patients and trialists (such as "trial") caused confusion, as did inaccuracies in patient information.Providing clear and accurate patient information is crucial, and patients need to be able to discuss their concerns about concepts such as randomisation if they are to give truly informed consent to participate in randomised controlled trials.
Maintenance Treatment with Thalidomide after Autologous Transplantation for Myeloma : First Analysis of a Prospective Randomized Study of the Intergroupe Francophone du Myelome (IFM 99 02).
Authors: Michel Attal, Jean-Luc Harousseau, Serge Leyvraz, Chantal Doyen, Cyrille Hulin, Lofti Benboubker, Thierry Facon, Jean-Henri Bourhis, Laurent Garderet, Jean-Jacques Sotto, Mauricette Michallet, Marc Renaud, Laurent Voillat, Christian Berthou, Gerald Marrit, Mathieu Monconduit, Bertrand Coiffier, Denis Caillot
Journal: Blood (2004)
Vaccinated Populations Can Get Flu
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Biochemistry, Washington
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The case for boards in clinical pharmacology
Authors: J. R. DiPalma
Journal: JAMA (1980)

THERE is an intense and active debate concerning the need for board certification among the three major societies that represent clinical pharmacology. In fact, a task force composed of members of the American College of Clinical Pharmacology (ACCP), the American Society for Clinical Pharmacology and Therapeutics (ASCPT), and the Clinical Pharmacology Division of the American Society for Pharmacology and Experimental Therapeutics (ASPET) is now at work to resolve this problem. The need to address this problem has arisen because the American Board of Clinical Pharmacology was actually incorporated in August 1976 by a group of distinguished clinical pharmacologists. This board has the moral support of the ACCP but is independent of the three societies. The board has agreed to delay its first examination and confirmation to the American Board of Medical Specialists until the task force has completed its deliberations. It is pertinent to restate here the reasoning, the pros
Omeprazole in duodenal ulceration: acid inhibition, symptom relief, endoscopic healing, and recurrence. Cooperative study.
Authors: J Meyrick-Thomas, J Misiewicz, I Trotman, E Boyd, J Wilson, G Wormsley, R Pounder, B Sharma, N Collier, J Spencer, J Thompson, J Baron, A Bush, L Cope, M Daly, A Howe, Mrs Howe, Lindknr Steen, Fleming Lund, Ole Nielsen, Steen Lindkmr Jensen
Journal: BMJ (1984)

In a preliminary study to compare the effects of different doses of omeprazole 44 patients with endoscopically diagnosed duodenal ulceration randomly received omeprazole 20 mg, 30 mg, 40 mg, or 60 mg daily for four weeks. After four weeks the ulcer had healed in 41 of the 43 patients who completed the course of treatment; the proportions of patients whose ulcer healed were similar between the four dosage groups. Most patients were symptom free after one week of treatment. Seven patients reported a total of eight adverse events. With the exception of one patient who had persistent nausea and was withdrawn from the study, all the adverse events resolved spontaneously during continued treatment with the same dose of omeprazole. Pentagastrin tests were performed before the study and after four weeks' treatment. The mean inhibition of peak acid output measured 24 hours after the last dose was 61%, 94%, 91%, and 81% with omeprazole 20 mg, 30 mg, 40 mg, and 60 mg respectively. During the first six months after the end of treatment 11 out of 36 patients had a symptomatic, endoscopically diagnosed recurrence of ulceration; the median time to relapse was 10 (range 6-23) weeks.
Hematology
Authors: K. B. Miller
Journal: JAMA (1993)

The application of recent advances in protein biochemistry and molecular and cellular biology continues to dominate the field of hematology. These advances in basic and applied research have led to new understandings of disease processes, diagnostic studies, and a new generation of therapeutics. The clinical application of these new technologies has introduced novel approaches to treatment and diagnosis of many hematologic disorders. Acute promyelocytic leukemia accounts for approximately 10% to 15% of all patients with acute leukemia. It is characterized by a unique and diagnostic cytogenetic marker involving chromosomes 15 and 17 t(15;17). The chromosome break point on chromosome 17 has been mapped to the site of the retinoic acid α-receptor.<sup>1</sup>The retinoic acid receptor is a member of a family of steroid hormone nuclear receptors that are important in the regulation and control of normal and malignant cellular differentiation and proliferation.<sup>2</sup>In acute promyelocytic leukemia, the cytogenetic
ACCESSORY SINUS DISEASE AND CHOKED DISK
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase I/II study of weekly topotecan and gefitinib in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer.
Authors: Anca Chelariu- Raicu, Charles F. Levenback, Brian M. Slomovitz, Diane C. Bodurka, David Marc Gershenson, Robert L. Coleman
Journal: Journal of Clinical Oncology (2020)

6059 Background: The epidermal growth factor receptor (EGFR) is expressed in many types of cancer. Fifty to 70% of epithelial ovarian can overexpress EGFR, and its expression has been correlated with poor prognosis features in many cases. While these tumors are chemosensitive to platinum-based therapy, chemoresistance often develops. We conducted a phase I/II trial to examine the efficacy, safety, and toxicity of gefitinib, a tyrosine kinase inhibitor, combined with topotecan in women with recurrent ovarian cancer with EGFR receptor positivity (1+ or greater). Methods: Patients with measurable, recurrent or persistent cancer after treatment with a platinum and paclitaxel-containing regimen were eligible for this study (n = 19). We first used “run-in” dose escalation, in which a conventional 3+3 algorithm was used. Initial treatment was gefitinib 250 mg oral dose daily and topotecan at a dose of 2.0 mg/m 2 on days 1, 8, and 15, with cycles repeated every 28 days. Dose escalations were planned for topotecan (Dose Levels 1–3: 2, 3, 4 mg/m 2 ) until the MTD was reached. Next, an additional 10 patients with refractory or progressive ovarian cancer were enrolled in the phase II study. Results: 19 patients received a total of 61 cycles. Median age was 60 years. Histological types of treated patients included 73% serous (n = 14), 12.5% mixed (n = 2), 12.5% transitional (n = 2) and 6.3% clear cell (n = 1). There were 3 patients treated at dose level 1, 3 patients at dose level 2, and 3 patients treated at dose level 3. The maximum tolerated dose was topotecan 4.0mg/m 2 IV days 1, 8 and 15, and gefitinib 250mg p.o. QD x28 days. Therefore, dose level 3 was used for the Phase II portion of the trial. Of the 19 patients included in the phase I/II, 3 patients were inevaluable for response to therapy due to toxicity, missed therapy or decline in performance status. Of the 16 patients, 81% patients (n = 13) had progressive disease, 12.5% stable disease (n = 2), and 6% partial response (n = 1). We assessed all 19 patients for adverse events; 60% had treatment-related grade 3 events, primarily blood disorders such as anemia (n = 3, 16%), neutrophil count decrease (n = 4, 21%). Conclusions: This prospective phase I/II clinical trial failed to show sufficient clinical activity of topotecan in combination with gefitinib in patients with EGFR-positive recurrent ovarian, fallopian tube, or peritoneal cancers. The drug combination was relatively well-tolerated in this cohort. As such, the study did not proceed to the next accrual goal secondary to the lack of response. Clinical trial information: NCT00317772.
Hirsutes.
Authors: G M Besser, M Witt
Journal: BMJ (1971)

In hirsutes there is an excessive growth of hair occurring on the face, breasts, limbs, or abdomen.In women such hair growth may present either without other abnormalities or be accompanied by other features of virilization such as hyper- trophy of the clitoris; deepening of the voice; acne; breast atro- phy; muscle hypertrophy; thinning of the scalp hair with temporal recession; and oligomenorrhoea or amenorrhoea.
Editorial Board
Authors: Katrina Lythgoe, Paul Craze, Jan Kastelein, Loek De Weerd, S Barrett, Canada Bell, B Bohannan, Usa Callaway, S Carpenter, J Madison, P Clark, R Dirzo, A Dobson, M Donoghue, D Erwin, W Laurance, Australia Cairns, R Mace, H May, R Nesse, S Otto, L Partridge, A Read, D Presgraves, C Simon, Usa Worm
Journal: Trends in Ecology & Evolution (2010)
Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies
Authors: Michael C. Heinrich, Charles D. Blanke, Brian J. Druker, Christopher L. Corless
Journal: Journal of Clinical Oncology (2002)

Activation of the KIT tyrosine kinase by somatic mutation has been documented in a number of human malignancies, including gastrointestinal stromal tumor (GIST), seminoma, acute myelogenous leukemia (AML), and mastocytosis. In addition, paracrine or autocrine activation of this kinase has been postulated in numerous other malignancies, including small-cell lung cancer and ovarian cancer. In this review, we discuss the rationale for and development of KIT tyrosine kinase inhibitors for the treatment of human malignancies.Studies were identified through a MEDLINE search, review of bibliographies of relevant articles, and review of abstracts from national meetings.Four tyrosine kinase inhibitors that have activity against KIT are currently being used in clinical trials, and one, STI571, has recently been approved by the United States Food and Drug Administration for treating patients with chronic myelogenous leukemia. The role of KIT inhibitors in treating KIT-positive malignancies is reviewed.Targeted therapy to inhibit the kinase activity of KIT is a rational approach to the treatment of KIT-positive malignancies. Two key factors are the potency of a given inhibitor and the relative contribution of KIT activation to the growth of the tumor. Given our current understanding of KIT activity in human malignancy, the best candidate diseases for treatment with KIT inhibitors are GIST, mastocytosis, seminoma and possibly some cases of AML. Additionally, KIT inhibitors may play an adjunctive role in diseases such as small-cell lung cancer, in which KIT activation is secondary to ligand binding rather than an acquired mutation.
pH and lactate imaging of atherosclerotic plaques: Introducing a 3 F 360 degree side-viewing near infrared spectroscopic catheter to monitor metabolic activity of atherosclerotic plaque Tania Khan, Babs Soller, Peter Melling, Mohammed Asif, Mohammad Madjid, Ward Casscells, Morteza Naghavi. University of Texas-Houston, Houston, TX, University of Massachusetts, Worchester, MA
Journal: Journal of the American College of Cardiology (2001)
Macrophage scavenger receptor 1 mediates lipid-induced inflammation in human obesity-related non-alcoholic fatty liver disease
Authors: Olivier Govaere, Nuria Martinez-Lopez, Sine K. Petersen, Rosellina Mancina, Pierre Bel Lassen, Rebecca Darlay, Julien Peltier, Ramy Younes, Dina Tiniakos, Guruprasad Aithal, Michael Allison, Hannele Yki-Järvinen, Jean-François Dufour, Mattias Ekstedt, Sven Francque, Salvatore Petta, Elisabetta Bugianesi, Jörn M. Schattenberg, Chris Day, Heather Cordell, Karine Clément, Stefano Romeo, Vlad Ratziu, Ann K. Daly, Quentin Anstee, Matthias Trost, Anetta S. Hartlova
Journal: Journal of Hepatology (2020)
THE PHYSICAL QUALITIES OF AVIATORS
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Extrahepatic bile duct growth in mice repeatedly injected with human normal serum, IgA-deficient serum or purified secretory IgA
Authors: P Solbreux
Journal: Hepatology (1991)

Another group of researchers has reported that seven intraperitoneal injections into mice of purified human serum IgA or normal human serum–but not IgA-deficient serum, mouse serum or saline–induced considerable growth of the extrahepatic bile duct epithelium. They stated that heterologous IgA was principally responsible for this effect. We have quantitated this growth by another method: enumeration of total and radiolabeled nuclei of the lumenal and glandular epithelium in transverse duct sections after tritiated thymidine injection and autoradiography. Our data show maximal incorporation between 18 and 24 hr after the last injection, with the highest labeling index in the lumenal epithelium after only three injections and before any duct enlargement. After four to seven injections, thymidine incorporation continued in juxtalumenal glands, together with massive glandular proliferation into the thickening wall and obvious inflammation. These changes were more pronounced in the liver-proximal part of the duct without affecting intrahepatic duct and gallbladder epithelia. Subcutaneous serum injections were less active. We confirm the inactivity of buffered saline, but, unlike previous authors, demonstrate strong activity in purified human milk secretory IgA and in IgA-deficient serum. We suggest that this different approach of quantitating epithelial proliferation will allow comparison of the bile duct growth effects of different, well-characterized human and animal IgA preparations. (HEPATOLOGY 1991;13:735–742.)